Cat. No.: HY-N6866

Gomisin N

Avis client

Based on 1 Customer Validation

Gomisin N is an orally active lignan compound. Gomisin N can be isolated from Schisandra chinensis. Gomisin N induces Apoptosis in a variety of cells. Gomisin N activates AMPK, Akt, MAPK/ERK, Nrf2, caspase-3 and PARP-1. Gomisin N inhibits GSK3β, nitric oxide (NO), and proinflammatory cytokines (IL-1β, IL-6, TNF-α). Gomisin N has anti-inflammatory, antioxidant, anti-obesity, anti-diabetic, and anti-melanogenesis activities. Gomisin N has anti-tumor activity against cervical cancer and liver cancer. Gomisin N improves Alzheimer's disease.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.94%
CAS No.: 69176-52-9
Formule: C₂₃H₂₈O₆
Masse moléculaire:400.46

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Gomisin N Chemical Structure

CAS No.: 69176-52-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]

GSK-3β

PARP-1

Caspase-3

IL-1β

IL-6

Voir tous les produits spécifiques à Isoform AMPK :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform Caspase :

Voir tous les produits spécifiques à Isoform PARP :

Voir tous les produits spécifiques à Isoform GSK-3 :

Voir tous les produits spécifiques à Isoform NO Synthase :

Voir tous les produits spécifiques à Isoform Interleukin Related :

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	IC₅₀	>100 μM Compound: 15	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 27919656]
HL-60	IC₅₀	52.4 μM Compound: 9	Cytotoxicity against human HL60 cells by XTT assay Cytotoxicity against human HL60 cells by XTT assay	[PMID: 16562834]
MDA-MB-231	IC₅₀	>100 μM Compound: Gomisin N	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 18063366]
SK-HEP1	IC₅₀	>100 μM Compound: Gomisin N	Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay	[PMID: 18063366]

In Vitro

Gomisin N (100 μM, 30 min) enhances TRAIL-induced apoptosis in Hela cells^[1].
Gomisin N (10-100 μM; 30 min-6 h) activates AMPK and Akt signaling and stimulates glucose uptake in C2C12 myotubes^[2].
Gomisin N (2.5-20 μM; 1 h) shows anti-inflammatory effects in LPS-stimulated Raw 264.7 cells, reducing nitric oxide (NO) production and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) expression^[3].
Gomisin N (25-100 μM; 48 h) reduces viability of HepG2 and HCCLM3 cells^[5].
Gomisin N (40-320 μM; 24 h) significantly induces anti-proliferative and pro-apoptotic effects in HepG2 cells^[6].
Gomisin N (10-100 μM; 16 h) shows protective effect against endoplasmic reticulum stress-induced hepatic steatosis in HepG2 cells^[8].
Gomisin N (1-10 μM; 72 h) inhibits melanogenesis through activating the PI3K/Akt and MAPK/ERK signaling pathways in Melan-A cells^[9].
Gomisin N (50 μM; 24 h) exerts an antioxidant effect by inhibiting GSK3β, activating the Nrf2 signaling pathway in H₂O₂-treated SH-SY5Y/APP695swe cells^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

Hela cells treated with TRAIL
Concentration:

100 μM
Incubation Time:

30 min
Result:

Significantly enhanced the cleavage of caspase-3 and PARP-1.
Enhanced TRAIL-induced apoptosis.

Real Time qPCR^[8]

Cell Line:

HepG2
Concentration:

10 μM, 50 μM, 100 μM
Incubation Time:

Pre-incubation for 16 h
Result:

Inhibited the expression of ER stress markers GRP78, CHOP, and XBP-1.
Inhibited the expression of inflammatory genes IL-6, TNF-α, and MCP-1 and lipogenic genes FAS, ACC1, and GPAT.

In Vivo

Gomisin N (20 mg/kg; p.o.; every day; 6 weeks) reduces hyperglycemia and improves glucose tolerance in high-fat diet (HFD)-induced obese C57BL/6 mice^[2].
Gomisin N (2-10 mg/kg; p.o.; 3 times per week; 8 weeks) prevents HFD-induced obesity and ameliorates hepatic steatosis in C57BL/6 mice^[4].
Gomisin N (1-30 mg/kg; p.o.; 4 days) alleviates Tunicamycin (HY-A0098)-induced hepatic endoplasmic reticulum stress and triglyceride accumulation and improves liver injury in C57BL/6 mice^[8].
Gomisin N (10-20 mg/kg; i.g.; 2 months) can improve the learning and memory abilities of AD rats induced by Aβ_25-35, reduce the area of Aβ plaques in the hippocampus and cortex, increase the number of neurons, and improve the oxidative stress state^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice (male, 6-week-old) + high-fat diet (HFD)-induced obese model^[2]
Dosage:

20 mg/kg
Administration:

Oral gavage (p.o.), once a day for 6 weeks
Result:

Reduced HFD-induced fasting glucose and insulin levels.
Lowered blood glucose levels at 30-120 min after glucose loading.
Increased the phosphorylation of AMPK and Akt.
Increased the ratio of plasma membrane GLUT4 to cytoplasmic GLUT4.
Stimulated the expression of mitochondria biogenesis genes in the skeletal muscle.

Animal Model:

C57BL/6 mice (male and female, 8-week-old), Tunicamycin-induced hepatic steatosis model^[8]
Dosage:

1 mg/kg, 30 mg/kg
Administration:

Oral gavage (p.o.), 4 days
Result:

Inhibited the increase in liver TG levels and the expression of ER stress markers.
Decreased serum GOT and GPT levels.

Chemical Information

CAS No. 69176-52-9
Appearance Solid
Masse moléculaire 400.46
Formule C₂₃H₂₈O₆
Color White to off-white
SMILES

COC1=C2OCOC2=CC(C[C@@H]3C)=C1C(C(C[C@H]3C)=CC(OC)=C4OC)=C4OC
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (249.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4971 mL

12.4856 mL

24.9713 mL

5 mM

0.4994 mL

2.4971 mL

4.9943 mL

10 mM

0.2497 mL

1.2486 mL

2.4971 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (291 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Inoue H, et al. Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5. Int J Oncol. 2012 Apr;40(4):1058-65. [Content Brief]

[2]. Jung DY, et al. Antidiabetic effect of gomisin N via activation of AMP-activated protein kinase. Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):587-593. [Content Brief]

[3]. Oh SY, et al. Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated from the fruit of Schisandra chinensis. Biosci Biotechnol Biochem. 2010;74(2):285-91. [Content Brief]

[4]. Jang MK, et al. Gomisin N inhibits adipogenesis and prevents high-fat diet-induced obesity. Sci Rep. 2017 Jan 9;7:40345. [Content Brief]

[5]. Zhu PL, et al. Gomisin N Exerts Anti-liver Cancer Effects and Regulates PI3K-Akt and mTOR-ULK1 Pathways in Vitro. Biol Pharm Bull. 2020;43(8):1267-1271. [Content Brief]

[6]. Yim SY, et al. Gomisin N isolated from Schisandra chinensis significantly induces anti-proliferative and pro-apoptotic effects in hepatic carcinoma. Mol Med Rep. 2009 Sep-Oct;2(5):725-32. [Content Brief]

[7]. Takimoto Y, et al. Gomisin N in the herbal drug gomishi (Schisandra chinensis) suppresses inducible nitric oxide synthase gene via C/EBPβ and NF-κB in rat hepatocytes. Nitric Oxide. 2013 Jan 15;28:47-56. [Content Brief]

[8]. Jang MK, et al. Protective Effect of Gomisin N against Endoplasmic Reticulum Stress-Induced Hepatic Steatosis. Biol Pharm Bull. 2016 May 1;39(5):832-8. [Content Brief]

[9]. Chae JK, et al. Gomisin N Inhibits Melanogenesis through Regulating the PI3K/Akt and MAPK/ERK Signaling Pathways in Melanocytes. Int J Mol Sci. 2017 Feb 22;18(2):471. [Content Brief]

[10]. Song M, et al. Gomisin N rescues cognitive impairment of Alzheimer's disease by targeting GSK3β and activating Nrf2 signaling pathway. Phytomedicine. 2024 Sep;132:155811. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4971 mL	12.4856 mL	24.9713 mL	62.4282 mL
	5 mM	0.4994 mL	2.4971 mL	4.9943 mL	12.4856 mL
	10 mM	0.2497 mL	1.2486 mL	2.4971 mL	6.2428 mL
	15 mM	0.1665 mL	0.8324 mL	1.6648 mL	4.1619 mL
	20 mM	0.1249 mL	0.6243 mL	1.2486 mL	3.1214 mL
	25 mM	0.0999 mL	0.4994 mL	0.9989 mL	2.4971 mL
	30 mM	0.0832 mL	0.4162 mL	0.8324 mL	2.0809 mL
	40 mM	0.0624 mL	0.3121 mL	0.6243 mL	1.5607 mL
	50 mM	0.0499 mL	0.2497 mL	0.4994 mL	1.2486 mL
	60 mM	0.0416 mL	0.2081 mL	0.4162 mL	1.0405 mL
	80 mM	0.0312 mL	0.1561 mL	0.3121 mL	0.7804 mL
	100 mM	0.0250 mL	0.1249 mL	0.2497 mL	0.6243 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Gomisin N

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library